NCT00389974View on ClinicalTrials.gov

Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Cervical AdenocarcinomaCervical Adenosquamous Cell CarcinomaCervical Squamous Cell CarcinomaRecurrent Cervical CancerStage IVB Cervical Cancer
Interventions
DRUG

sunitinib malate

Given PO

Trial Locations (1)

K7L 3N6

National Cancer Institute of Canada Clinical Trials Group, Kingston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00389974 - Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery | Biotech Hunter | Biotech Hunter